CagriSema's FDA Decision Window: What Novo Nordisk's Dual-Peptide Obesity Combination Means for Researchers and UK Access

Key takeaways

• Novo Nordisk filed a New Drug Application for CagriSema with the FDA on 18 December 2025; a decision is expected in Q4 2026, with October widely cited as the indicative date based on a standard ten-to-twelve-month review clock.
• CagriSema combines two distinct peptide mechanisms: semaglutide (GLP-1 receptor agonist) and cagrilintide (long-acting amylin analogue), making it the first fixed-dose amylin–GLP-1 injectable combination to seek regulatory approval.
• Phase 3 REDEFINE 1 data showed 22.7% average weight loss over 68 weeks on a full-adherence estimand; the REDEFINE 4 head-to-head against tirzepatide 15 mg failed to meet its non-inferiority primary endpoint.
• No MHRA submission or EMA application has been publicly confirmed by Novo Nordisk, placing UK access at least twelve to twenty-four months behind a US approval. NICE appraisal would add further delay for NHS access.
• Cagrilintide cannot be compounded under current FDA rules, meaning any CagriSema product offered outside clinical trials is, by definition, not the trial drug.

What CagriSema is and why the peptide mechanism matters

CagriSema is an investigational once-weekly subcutaneous injection that pairs two long-acting peptides in a single fixed dose: semaglutide 2.4 mg — the GLP-1 receptor agonist already approved as Wegovy — and cagrilintide 2.4 mg, a synthetic amylin analogue developed by Novo Nordisk.

Amylin is a pancreatic hormone co-secreted with insulin. Its natural role is to slow gastric emptying, suppress post-meal glucagon secretion, and signal satiety to the hypothalamus. Cagrilintide is engineered for prolonged half-life, enabling once-weekly dosing that mirrors the semaglutide schedule. According to Novo Nordisk, CagriSema is being investigated as a treatment for adults with overweight or obesity (the REDEFINE programme) and adults with type 2 diabetes (the REIMAGINE programme).

The combination approach is conceptually distinct from GLP-1/GIP dual agonists such as tirzepatide, which act on incretin receptors. Amylin receptor signalling operates through a separate pathway, so the theoretical rationale for combining it with GLP-1 is additive rather than overlapping suppression of appetite. Whether that translates into clinically meaningful superiority over available single-mechanism drugs is precisely the question the REDEFINE trials were designed to answer.

Phase 3 data: what the REDEFINE programme shows

REDEFINE 1 (non-diabetic obesity)

REDEFINE 1 enrolled 3,417 adults with overweight or obesity without type 2 diabetes and ran for 68 weeks. On the trial-product (full-adherence) estimand, CagriSema produced average weight loss of 22.7%, and 40.4% of participants lost at least 25% of body weight, according to Second Nature's review of the REDEFINE data. On the treatment-policy estimand — reflecting real-world dropout and off-protocol medication use — weight loss was approximately 20.4%, according to GLP-1 Picks.

For context, the pivotal Wegovy (semaglutide 2.4 mg) trials showed approximately 15% weight loss and Zepbound (tirzepatide) achieved around 21% in SURMOUNT-1. CagriSema's REDEFINE 1 result therefore sits near the upper bound of what has been demonstrated in phase 3 obesity pharmacotherapy to date.

REDEFINE 2 (type 2 diabetes)

In REDEFINE 2, adults living with type 2 diabetes lost an average of 15.7% of body weight on the full-adherence estimand at 68 weeks, according to Second Nature. Novo Nordisk has stated it will approach regulatory authorities to discuss the pathway for CagriSema in type 2 diabetes following results from REIMAGINE 1 and REDEFINE 3.

REDEFINE 4: the head-to-head against tirzepatide

The most consequential data point for competitive positioning emerged in February 2026. The REDEFINE 4 trial (NCT06131437) enrolled approximately 800 adults with obesity and ran for 84 weeks, comparing CagriSema directly with tirzepatide 15 mg. According to Drugs.com's reporting of the trial result, CagriSema achieved 23.0% weight loss but did not meet the pre-specified non-inferiority margin compared to tirzepatide 15 mg, which delivered approximately 25.5% weight loss. Failing the non-inferiority endpoint does not preclude approval — the FDA assesses applications against placebo-controlled trials, not competitor benchmarks — but it eliminates any claim of superior or equivalent efficacy against the current market leader.

FDA review: where the decision stands

Novo Nordisk filed the CagriSema NDA on 18 December 2025, based primarily on REDEFINE 1 and REDEFINE 2. Under a standard ten-to-twelve-month FDA review clock for a new molecular entity, a decision falls in Q4 2026. As of July 2026, neither the agency nor Novo Nordisk had publicly confirmed an official PDUFA date, and the filing does not appear to carry Priority Review designation, which would have compressed the timeline to six months.

According to Life Science Daily News, no advisory committee meeting has been scheduled, although the agency retains discretion to convene an external expert panel. Observers will watch for any FDA information request, the agency's reading of the combined gastrointestinal tolerability profile, and any signal on how the reviewing division interprets the REDEFINE 4 head-to-head result in the context of the primary placebo-controlled filing data.

UK and European regulatory status

For UK research-procurement professionals, the most operationally significant fact is the absence of any publicly confirmed regulatory filing outside the United States. Novo Nordisk has not confirmed an EMA submission for weight management, and no MHRA pathway has been announced for the United Kingdom.

As of May 2026, no MHRA submission has been publicly confirmed. MHRA reviews of new medicines typically take six to twelve months from submission, meaning that even if a UK filing were made immediately following a US approval, private-market access would be unlikely before late 2027. NHS access via NICE technology appraisal would follow on a further timeline. The MHRA's EC Decision Reliance Procedure — which allows the agency to leverage EMA assessments — is not applicable in the absence of a confirmed EMA application.

As of July 2026, none of the "next wave" weight-loss drugs including CagriSema is licensed by the MHRA, meaning the medicines available for UK prescription remain tirzepatide (Mounjaro) and semaglutide (Wegovy/Ozempic).

Compounding position and grey-market risk

UK labs sourcing peptides for research purposes should note that cagrilintide's compounding status creates a clear delineation. According to The RX Index, the FDA has confirmed that cagrilintide cannot be compounded, which means there is no legitimate compounded pathway for CagriSema. Any product marketed under the CagriSema name outside a Novo Nordisk-sponsored clinical trial is not the investigational drug and carries no validated purity, concentration, or manufacturing standard.

Semaglutide, the GLP-1 component, has its own separate compounding history. FDA enforcement discretion for compounded semaglutide ended in early 2025 following resolution of the drug shortage, and the compound is no longer eligible for 503A or 503B compounding. Combined, these two positions mean CagriSema as a formulation has no legitimate non-trial access route in the US or UK.

What approval or rejection would mean for the research landscape

A positive FDA decision would mark the first regulatory validation of amylin–GLP-1 combination therapy and would likely accelerate academic and commercial interest in amylin-receptor biology — an area that has remained relatively underexplored in the peptide research literature since pramlintide (Symlin) was approved in 2005 as a short-acting monomeric amylin analogue.

For researchers working in metabolic peptide pharmacology, the mechanistic distinction matters: cagrilintide acts primarily via amylin receptors (which form heterodimers with calcitonin receptors) rather than the incretin axis. A successful approval would provide the first clinical proof-of-concept that combining two mechanistically distinct long-acting peptides in a single formulation is approvable and commercially viable, potentially expanding the design space for future peptide combination programmes.

A rejection, or a Complete Response Letter requesting additional data, would raise questions about whether the combined gastrointestinal tolerability profile — two appetite-suppressing peptides with partially overlapping nausea mechanisms — is adequate, and whether the REDEFINE 4 head-to-head result affects the agency's benefit-risk assessment in a competitive market with already-approved alternatives.

The outcome of the CagriSema FDA review will indicate whether combination therapy becomes the next standard in obesity care, or whether single-molecule agents continue to define the field.